MXCT

Healthcare Medical Devices

MaxCyte, Inc.

$1.07
-0.02 -1.87% today

Price History

Not enough data

Key Stats

Market Cap
110.43M
Avg Volume
715,067
EPS
-$0.34
52W High
$1.87
52W Low
$0.64
Div. Yield
0.0%

Analyst Ratings

Buy
0
Str Buy
5
Buy
1
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
-4.36
P/B Ratio
0.72
P/S Ratio
3.56
EV/EBITDA
-0.73
EV/Revenue
0.71

Margins

Gross Margin 79.2%
Operating Margin (140.7%)
Net Margin (114.8%)
EBITDA Margin (97.5%)

Growth & Returns

Revenue Growth (YoY)
(14.5%)
Return on Equity
(20.4%)
Return on Assets
(10.6%)

Liquidity & Leverage

Current Ratio
12.26
Quick Ratio
11.08
Debt / Equity
0.11
Total Cash
105.69M
Total Debt
17.25M

About

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

www.maxcyte.com